PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions

Deborah Saraggi, Francesca Galuppini, Andrea Remo, Emanuele D.L. Urso, Deborah Bacchin, Roberta Salmaso, Cristiano Lanza, Riccardo Q. Bao, Giuseppe N. Fanelli, Vincenza Guzzardo, Claudio Luchini, Marco Scarpa, Fabio Farinati, Matteo Fassan, Massimo Rugge

Research output: Contribution to journalArticle

Abstract

Aims: PD-1/PD-L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD-L1 expression in ampulla of Vater carcinoma and its pre-invasive lesions. Methods and results: We assessed the immunohistochemical expression of PD-L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD-L1 was expressed in seven of 26 (26.9%) invasive carcinomas and three of 50 (6.0%) dysplastic samples. Most of the PD-L1-positive tumours (seven of 10) were intestinal-type and poorly differentiated (G3). The number of PD-L1-positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD-L1 expression. Four of the carcinomas were mismatch repair-deficient and two of these were PD-L1-positive. Furthermore, mismatch repair-deficient lesions showed a significantly higher average of PD-L1-positive stromal lymphoid cells than those of neoplastic PD-L1-negative samples (62.8 versus 21.6; P < 0.001). Conclusions: The present results suggest a role of the PD-1/PD-L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.

Original languageEnglish
Pages (from-to)470-474
Number of pages5
JournalHistopathology
Volume71
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Ampulla of Vater
DNA Mismatch Repair
Carcinoma
Stromal Cells
Immunotherapy
Adenocarcinoma
Lymphocytes
Neoplasms
Mucous Membrane
Drug Therapy
Therapeutics
Proteins

Keywords

  • ampulla of Vater
  • biomarkers
  • dysplasia
  • PD-L1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Saraggi, D., Galuppini, F., Remo, A., Urso, E. D. L., Bacchin, D., Salmaso, R., ... Rugge, M. (2017). PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology, 71(3), 470-474. https://doi.org/10.1111/his.13254

PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. / Saraggi, Deborah; Galuppini, Francesca; Remo, Andrea; Urso, Emanuele D.L.; Bacchin, Deborah; Salmaso, Roberta; Lanza, Cristiano; Bao, Riccardo Q.; Fanelli, Giuseppe N.; Guzzardo, Vincenza; Luchini, Claudio; Scarpa, Marco; Farinati, Fabio; Fassan, Matteo; Rugge, Massimo.

In: Histopathology, Vol. 71, No. 3, 01.09.2017, p. 470-474.

Research output: Contribution to journalArticle

Saraggi, D, Galuppini, F, Remo, A, Urso, EDL, Bacchin, D, Salmaso, R, Lanza, C, Bao, RQ, Fanelli, GN, Guzzardo, V, Luchini, C, Scarpa, M, Farinati, F, Fassan, M & Rugge, M 2017, 'PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions', Histopathology, vol. 71, no. 3, pp. 470-474. https://doi.org/10.1111/his.13254
Saraggi D, Galuppini F, Remo A, Urso EDL, Bacchin D, Salmaso R et al. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology. 2017 Sep 1;71(3):470-474. https://doi.org/10.1111/his.13254
Saraggi, Deborah ; Galuppini, Francesca ; Remo, Andrea ; Urso, Emanuele D.L. ; Bacchin, Deborah ; Salmaso, Roberta ; Lanza, Cristiano ; Bao, Riccardo Q. ; Fanelli, Giuseppe N. ; Guzzardo, Vincenza ; Luchini, Claudio ; Scarpa, Marco ; Farinati, Fabio ; Fassan, Matteo ; Rugge, Massimo. / PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. In: Histopathology. 2017 ; Vol. 71, No. 3. pp. 470-474.
@article{4ea5303b67844fcb8dc87b0d79b0903a,
title = "PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions",
abstract = "Aims: PD-1/PD-L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD-L1 expression in ampulla of Vater carcinoma and its pre-invasive lesions. Methods and results: We assessed the immunohistochemical expression of PD-L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD-L1 was expressed in seven of 26 (26.9{\%}) invasive carcinomas and three of 50 (6.0{\%}) dysplastic samples. Most of the PD-L1-positive tumours (seven of 10) were intestinal-type and poorly differentiated (G3). The number of PD-L1-positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD-L1 expression. Four of the carcinomas were mismatch repair-deficient and two of these were PD-L1-positive. Furthermore, mismatch repair-deficient lesions showed a significantly higher average of PD-L1-positive stromal lymphoid cells than those of neoplastic PD-L1-negative samples (62.8 versus 21.6; P < 0.001). Conclusions: The present results suggest a role of the PD-1/PD-L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.",
keywords = "ampulla of Vater, biomarkers, dysplasia, PD-L1",
author = "Deborah Saraggi and Francesca Galuppini and Andrea Remo and Urso, {Emanuele D.L.} and Deborah Bacchin and Roberta Salmaso and Cristiano Lanza and Bao, {Riccardo Q.} and Fanelli, {Giuseppe N.} and Vincenza Guzzardo and Claudio Luchini and Marco Scarpa and Fabio Farinati and Matteo Fassan and Massimo Rugge",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/his.13254",
language = "English",
volume = "71",
pages = "470--474",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions

AU - Saraggi, Deborah

AU - Galuppini, Francesca

AU - Remo, Andrea

AU - Urso, Emanuele D.L.

AU - Bacchin, Deborah

AU - Salmaso, Roberta

AU - Lanza, Cristiano

AU - Bao, Riccardo Q.

AU - Fanelli, Giuseppe N.

AU - Guzzardo, Vincenza

AU - Luchini, Claudio

AU - Scarpa, Marco

AU - Farinati, Fabio

AU - Fassan, Matteo

AU - Rugge, Massimo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Aims: PD-1/PD-L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD-L1 expression in ampulla of Vater carcinoma and its pre-invasive lesions. Methods and results: We assessed the immunohistochemical expression of PD-L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD-L1 was expressed in seven of 26 (26.9%) invasive carcinomas and three of 50 (6.0%) dysplastic samples. Most of the PD-L1-positive tumours (seven of 10) were intestinal-type and poorly differentiated (G3). The number of PD-L1-positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD-L1 expression. Four of the carcinomas were mismatch repair-deficient and two of these were PD-L1-positive. Furthermore, mismatch repair-deficient lesions showed a significantly higher average of PD-L1-positive stromal lymphoid cells than those of neoplastic PD-L1-negative samples (62.8 versus 21.6; P < 0.001). Conclusions: The present results suggest a role of the PD-1/PD-L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.

AB - Aims: PD-1/PD-L1 checkpoint immunotherapy has been proposed recently as a promising treatment in relapsed/refractory disease, used eventually in combination with traditional chemotherapy in different cancer settings. To date, no data are available concerning PD-L1 expression in ampulla of Vater carcinoma and its pre-invasive lesions. Methods and results: We assessed the immunohistochemical expression of PD-L1 in a series of 26 ampullary adenocarcinomas, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa samples. Moreover, in all cases DNA mismatch repair proteins status was investigated. PD-L1 was expressed in seven of 26 (26.9%) invasive carcinomas and three of 50 (6.0%) dysplastic samples. Most of the PD-L1-positive tumours (seven of 10) were intestinal-type and poorly differentiated (G3). The number of PD-L1-positive stromal lymphoid cells was significantly higher in dysplastic and invasive lesions than in the normal samples (P = 0.011). Nineteen dysplastic lesions and eight invasive carcinomas did not show any evident epithelial or stromal PD-L1 expression. Four of the carcinomas were mismatch repair-deficient and two of these were PD-L1-positive. Furthermore, mismatch repair-deficient lesions showed a significantly higher average of PD-L1-positive stromal lymphoid cells than those of neoplastic PD-L1-negative samples (62.8 versus 21.6; P < 0.001). Conclusions: The present results suggest a role of the PD-1/PD-L1 axis in ampullary adenocarcinomas, and therefore this may also prompt consideration of checkpoint immunotherapy as a novel promising treatment for these tumours.

KW - ampulla of Vater

KW - biomarkers

KW - dysplasia

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85021420278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021420278&partnerID=8YFLogxK

U2 - 10.1111/his.13254

DO - 10.1111/his.13254

M3 - Article

AN - SCOPUS:85021420278

VL - 71

SP - 470

EP - 474

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -